Altered redox status in the blood of psoriatic patients: involvement of NADPH oxidase and role of anti-TNF-α therapy

References

• Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A. The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 2012;51(4):389–95.
   PubMed Web of Science ®Google Scholar
• Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cell Mol Immunol 2012;9(4):302–9.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med 2009;47:891–905.
   PubMed Web of Science ®Google Scholar
• Gabr SA, Al-Ghadir AH. Role of cellular oxidative stress and cytochrome c in the pathogenesis of psoriasis. Arch Dermatol Res 2012;304(6):451–7.
   PubMed Web of Science ®Google Scholar
• Pujari VM, Suryakar AN, Ireddy S. Oxidants and antioxidant status in psoriasis patients. Biomed Res 2010;21(2):221–3.
   Web of Science ®Google Scholar
• Kadam DP, Suryakar AN, Ankush RD, Kadam CY, Deshpande KH. Role of oxidative stress in various stages of psoriasis. Indian J Clin Biochem 2010;25(4):388–92.
   PubMedGoogle Scholar
• Basavaraj KH, Vasu Devaraju P, Rao KS. Studies on serum 8-hydroxy guanosine (8-OHdG) as reliable biomarker for psoriasis. J Eur Acad Dermatol Venereol 2012; Jan 14, DOI: 10.1111/j.1468-3083.2011.04441.x.
   PubMed Web of Science ®Google Scholar
• Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Teixeira F. Dislipidemia and oxidative stress in mild and in severe psoriasis as a risk for cardiovascular disease. Clin Chim Acta 2001;303(1–2):33–9.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Barabino G, Caiti M, Cagnati P, Puppo F. Anti-tumor necrosis factor-α treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437–9.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557–65.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47(4):277–88.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56–60.
   PubMed Web of Science ®Google Scholar
• Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537–41.
   PubMed Web of Science ®Google Scholar
• Thalayasingam N, Isaacs JD. Anti-TNF therapy. Best Pract Res Clin Rheumatol 2011;25(4):549–67.
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, Gulli R, Spanò F, Puppo F. Update upon efficacy and safety of TNF-α inhibitors. Expert Opin Drug Saf 2012;11(1):1–5.
   PubMed Web of Science ®Google Scholar
• Baker EL, Coleman CI, Reinhart KM, Phung OJ, Kugelman L, Chen W, et al. Effect of biologic agents on non-PASI outcomes in moderate-to-severe plaque psoriasis: systematic review and meta-analyses. Dermatol Ther (Heidelb) 2012;2(1):9.
   PubMedGoogle Scholar
• Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277–9.
   PubMed Web of Science ®Google Scholar
• Mariappan N, Elks CM, Haque M, Francis J. Interaction of TNF with angiotensin II contributes to mitochondrial oxidative stress and cardiac damage in rats. PLoS One 2012;7(10):e46568.
   PubMedGoogle Scholar
• Chen XH, Zhao YP, Xue M, Ji CB, Gao CL, Zhu JG, et al. TNF-alpha induces mitochondrial dysfunction in 3T3-L1 adipocytes. Mol Cell Endocrinol 2010;328(1–2):63–9.
   PubMed Web of Science ®Google Scholar
• Moe KT, Aulia S, Jiang F, Chua YL, Koh TH, Wong MC, et al. Differential upregulation of Nox homologues of NADPH oxidase by tumor necrosis factor-alpha in human aortic smooth muscle and embryonic kidney cells. J Cell Mol Med 2006;10(1):231–9.
   PubMed Web of Science ®Google Scholar
• Yoshida LS, Tsunawaki S. Expression of NADPH oxidases and enhanced H(2)O(2)-generating activity in human coronary artery endothelial cells upon induction with tumor necrosis factor-alpha. Int Immunopharmacol 2008;8(10):1377–85.
   PubMed Web of Science ®Google Scholar
• Kim YS, Morgan MJ, Choksi S, Liu ZG. TNF-induced activation of the Nox1 NADPH oxidase and its role in the induction of necrotic cell death. Mol Cell 2007;26(5):675–87.
   PubMed Web of Science ®Google Scholar
• Cangemi R, Celestini A, Del Ben M, Pignatelli P, Carnevale R, Proietti M, et al. Role of platelets in NOX2 activation mediated by TNFα in heart failure. Intern Emerg Med 2012; Jul 28, DOI: 10.1007/s11739-012-0837-2.
   PubMed Web of Science ®Google Scholar
• Becatti M, Prignano F, Fiorillo C, Pescitelli L, Nassi P, Lotti T, et al. The involvement of Smac/DIABLO, p53, NF-kB, and MAPK pathways in apoptosis of keratinocytes from perilesional vitiligo skin: protective effects of curcumin and capsaicin. Antioxid Redox Signal 2010;13(9):1309–21.
   PubMed Web of Science ®Google Scholar
• Becatti M, Taddei N, Cecchi C, Nassi N, Nassi PA, Fiorillo C. SIRT1 modulates MAPK pathways in ischemic-reperfused cardiomyocytes. Cell Mol Life Sci 2012;69(13):2245–60.
   PubMed Web of Science ®Google Scholar
• Delves PJ, Martin SJ, Burton DR, Roitt IM, eds. Roitt's essential immunology. New York: Wiley-Blackwell; 2011. p. 546.
   Google Scholar
• Yiu KH, Yeung CK, Zhao CT, Chan JC, Siu CW, Tam S, et al. Prevalence and extent of subclinical atherosclerosis in patients with psoriasis. J Intern Med 2013; 273(3):273–82.
   Web of Science ®Google Scholar
• Gniadecki R, Kragballe K, Dam TN, Skov L. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011;164:1091–6.
   PubMed Web of Science ®Google Scholar
• Warren RB, Griffiths CE. The future of biological therapies. Semin Cutan Med Surg 2010;29:63–6.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, Kaloudi O, Cassarà E. Infliximab in psoriatic arthritis. J Rheumatol Suppl 2012;89:71–3.
   PubMedGoogle Scholar
• Perez-Alvarez R, Pérez-de-Lis M, Ramos-Casals M; BIOGEAS study group. Biologics-induced autoimmune diseases. Curr Opin Rheumatol 2013;25(1):56–64.
   PubMed Web of Science ®Google Scholar
• De Simone C, Murri R, Maiorino A, Venier A, Caldarola G. Management of recurrent cutaneous abscesses during therapy with infliximab. Clin Ther 2011;33(12):1993–6.
   PubMed Web of Science ®Google Scholar
• Papp KA, Dekoven J, Parsons L, Pirzada S, Robern M, Robertson L, et al. Biologic therapy in psoriasis: perspectives on associated risks and patient management. J Cutan Med Surg 2012;16(3):153–68.
   PubMed Web of Science ®Google Scholar
• Guerra I, Algaba A, Pérez-Calle JL, Chaparro M, Marín-Jiménez I, García-Castellanos R, et al. Induction of psoriasis with anti-TNF agents in patients with inflammatory bowel disease: a report of 21 cases. J Crohns Colitis 2012;6(5):518–23.
   PubMed Web of Science ®Google Scholar
• Alghamdi KM, Khurrum H, Rikabi A. Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg 2011;15(5):280–4.
   PubMed Web of Science ®Google Scholar
• Csiszar A, Labinskyy N, Smith K, Rivera A, Orosz Z, Ungvari Z. Vasculoprotective effects of anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol 2007;170(1):388–98.
   PubMed Web of Science ®Google Scholar
• Guzel A, Kanter M, Guzel A, Pergel A, Erboga M. Anti-inflammatory and antioxidant effects of infliximab on acute lung injury in a rat model of intestinal ischemia/reperfusion. J Mol Histol 2012;43(3):361–9.
   PubMed Web of Science ®Google Scholar
• Campanati A, Orciani M, Gorbi S, Regoli F, Di Primio R, Offidani A. Effect of biologic therapies targeting tumour necrosis factor-α on cutaneous mesenchymal stem cells in psoriasis. Br J Dermatol 2012;167(1):68–76.
   PubMed Web of Science ®Google Scholar